Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $9.2 million.

  • Addex Therapeutics' Liabilities and Shareholders Equity fell 3475.08% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 1027.84%. This contributed to the annual value of $12.1 million for FY2024, which is 13484.77% up from last year.
  • Latest data reveals that Addex Therapeutics reported Liabilities and Shareholders Equity of $9.2 million as of Q3 2025, which was down 3475.08% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Addex Therapeutics' Liabilities and Shareholders Equity ranged from a high of $19.1 million in Q1 2022 and a low of $3.8 million during Q1 2024
  • Its 4-year average for Liabilities and Shareholders Equity is $10.5 million, with a median of $10.3 million in 2025.
  • As far as peak fluctuations go, Addex Therapeutics' Liabilities and Shareholders Equity crashed by 5880.71% in 2023, and later skyrocketed by 17600.8% in 2025.
  • Quarter analysis of 4 years shows Addex Therapeutics' Liabilities and Shareholders Equity stood at $8.6 million in 2022, then plummeted by 39.13% to $5.2 million in 2023, then surged by 132.93% to $12.2 million in 2024, then dropped by 24.82% to $9.2 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $9.2 million for Q3 2025, versus $10.3 million for Q2 2025 and $10.5 million for Q1 2025.